Katherine B Howell1, Jacinta M McMahon1, Gemma L Carvill1, Dimira Tambunan1, Mark T Mackay1, Victoria Rodriguez-Casero1, Richard Webster1, Damian Clark1, Jeremy L Freeman1, Sophie Calvert1, Heather E Olson1, Simone Mandelstam1, Annapurna Poduri1, Heather C Mefford1, A Simon Harvey1, Ingrid E Scheffer2. 1. From the Departments of Neurology (K.B.H., M.T.M., V.R.-C., J.L.F., A.S.H., I.E.S.) and Radiology (S.M.), The Royal Children's Hospital, Melbourne; Department of Paediatrics (K.B.H., M.T.M., S.M., A.S.H., I.E.S.), The University of Melbourne; Murdoch Childrens Research Institute (K.B.H., M.T.M., J.L.F., A.S.H.), Melbourne; Epilepsy Research Centre (J.M.M., I.E.S.), Department of Medicine, University of Melbourne, Austin Health, Melbourne, Australia; Division of Genetic Medicine (G.L.C., H.C.M.), Department of Paediatrics, University of Washington, Seattle; Epilepsy Genetics Program (D.T., H.E.O., A.P.), Department of Neurology, Harvard Medical School, Boston Children's Hospital, MA; TY Nelson Department of Neurology and Neurosurgery (R.W.), The Children's Hospital at Westmead, Sydney; Department of Neurology (D.C.), Women's and Children's Hospital, Adelaide; Neurosciences Children's Health Queensland (S.C.), Lady Cilento Children's Hospital, Brisbane; and Florey Institute of Neuroscience and Mental Health (S.M., A.S.H., I.E.S.), Melbourne, Australia. 2. From the Departments of Neurology (K.B.H., M.T.M., V.R.-C., J.L.F., A.S.H., I.E.S.) and Radiology (S.M.), The Royal Children's Hospital, Melbourne; Department of Paediatrics (K.B.H., M.T.M., S.M., A.S.H., I.E.S.), The University of Melbourne; Murdoch Childrens Research Institute (K.B.H., M.T.M., J.L.F., A.S.H.), Melbourne; Epilepsy Research Centre (J.M.M., I.E.S.), Department of Medicine, University of Melbourne, Austin Health, Melbourne, Australia; Division of Genetic Medicine (G.L.C., H.C.M.), Department of Paediatrics, University of Washington, Seattle; Epilepsy Genetics Program (D.T., H.E.O., A.P.), Department of Neurology, Harvard Medical School, Boston Children's Hospital, MA; TY Nelson Department of Neurology and Neurosurgery (R.W.), The Children's Hospital at Westmead, Sydney; Department of Neurology (D.C.), Women's and Children's Hospital, Adelaide; Neurosciences Children's Health Queensland (S.C.), Lady Cilento Children's Hospital, Brisbane; and Florey Institute of Neuroscience and Mental Health (S.M., A.S.H., I.E.S.), Melbourne, Australia. scheffer@unimelb.edu.au.
Abstract
OBJECTIVE: De novo SCN2A mutations have recently been associated with severe infantile-onset epilepsies. Herein, we define the phenotypic spectrum of SCN2A encephalopathy. METHODS: Twelve patients with an SCN2A epileptic encephalopathy underwent electroclinical phenotyping. RESULTS: Patients were aged 0.7 to 22 years; 3 were deceased. Seizures commenced on day 1-4 in 8, week 2-6 in 2, and after 1 year in 2. Characteristic features included clusters of brief focal seizures with multiple hourly (9 patients), multiple daily (2), or multiple weekly (1) seizures, peaking at maximal frequency within 3 months of onset. Multifocal interictal epileptiform discharges were seen in all. Three of 12 patients had infantile spasms. The epileptic syndrome at presentation was epilepsy of infancy with migrating focal seizures (EIMFS) in 7 and Ohtahara syndrome in 2. Nine patients had improved seizure control with sodium channel blockers including supratherapeutic or high therapeutic phenytoin levels in 5. Eight had severe to profound developmental impairment. Other features included movement disorders (10), axial hypotonia (11) with intermittent or persistent appendicular spasticity, early handedness, and severe gastrointestinal symptoms. Mutations arose de novo in 11 patients; paternal DNA was unavailable in one. CONCLUSIONS: Review of our 12 and 34 other reported cases of SCN2A encephalopathy suggests 3 phenotypes: neonatal-infantile-onset groups with severe and intermediate outcomes, and a childhood-onset group. Here, we show that SCN2A is the second most common cause of EIMFS and, importantly, does not always have a poor developmental outcome. Sodium channel blockers, particularly phenytoin, may improve seizure control.
OBJECTIVE: De novo SCN2A mutations have recently been associated with severe infantile-onset epilepsies. Herein, we define the phenotypic spectrum of SCN2Aencephalopathy. METHODS: Twelve patients with an SCN2Aepileptic encephalopathy underwent electroclinical phenotyping. RESULTS:Patients were aged 0.7 to 22 years; 3 were deceased. Seizures commenced on day 1-4 in 8, week 2-6 in 2, and after 1 year in 2. Characteristic features included clusters of brief focal seizures with multiple hourly (9 patients), multiple daily (2), or multiple weekly (1) seizures, peaking at maximal frequency within 3 months of onset. Multifocal interictal epileptiform discharges were seen in all. Three of 12 patients had infantile spasms. The epileptic syndrome at presentation was epilepsy of infancy with migrating focal seizures (EIMFS) in 7 and Ohtahara syndrome in 2. Nine patients had improved seizure control with sodium channel blockers including supratherapeutic or high therapeutic phenytoin levels in 5. Eight had severe to profound developmental impairment. Other features included movement disorders (10), axial hypotonia (11) with intermittent or persistent appendicular spasticity, early handedness, and severe gastrointestinal symptoms. Mutations arose de novo in 11 patients; paternal DNA was unavailable in one. CONCLUSIONS: Review of our 12 and 34 other reported cases of SCN2Aencephalopathy suggests 3 phenotypes: neonatal-infantile-onset groups with severe and intermediate outcomes, and a childhood-onset group. Here, we show that SCN2A is the second most common cause of EIMFS and, importantly, does not always have a poor developmental outcome. Sodium channel blockers, particularly phenytoin, may improve seizure control.
Authors: Jan Larsen; Gemma L Carvill; Elena Gardella; Gerhard Kluger; Gudrun Schmiedel; Nina Barisic; Christel Depienne; Eva Brilstra; Yuan Mang; Jens Erik Klint Nielsen; Martin Kirkpatrick; David Goudie; Rebecca Goldman; Johanna A Jähn; Birgit Jepsen; Deepak Gill; Miriam Döcker; Saskia Biskup; Jacinta M McMahon; Bobby Koeleman; Mandy Harris; Kees Braun; Carolien G F de Kovel; Carla Marini; Nicola Specchio; Tania Djémié; Sarah Weckhuysen; Niels Tommerup; Monica Troncoso; Ledia Troncoso; Andrea Bevot; Markus Wolff; Helle Hjalgrim; Renzo Guerrini; Ingrid E Scheffer; Heather C Mefford; Rikke S Møller Journal: Neurology Date: 2015-01-07 Impact factor: 9.910
Authors: N A Singh; C Charlier; D Stauffer; B R DuPont; R J Leach; R Melis; G M Ronen; I Bjerre; T Quattlebaum; J V Murphy; M L McHarg; D Gagnon; T O Rosales; A Peiffer; V E Anderson; M Leppert Journal: Nat Genet Date: 1998-01 Impact factor: 38.330
Authors: Sarah E Heron; Kathryn M Crossland; Eva Andermann; Hilary A Phillips; Allison J Hall; Andrew Bleasel; Michael Shevell; Suha Mercho; Marie-Helene Seni; Marie-Christine Guiot; John C Mulley; Samuel F Berkovic; Ingrid E Scheffer Journal: Lancet Date: 2002-09-14 Impact factor: 79.321
Authors: Samuel F Berkovic; Sarah E Heron; Lucio Giordano; Carla Marini; Renzo Guerrini; Robert E Kaplan; Antonio Gambardella; Ortrud K Steinlein; Bronwyn E Grinton; Joanne T Dean; Laura Bordo; Bree L Hodgson; Toshiyuki Yamamoto; John C Mulley; Federico Zara; Ingrid E Scheffer Journal: Ann Neurol Date: 2004-04 Impact factor: 10.422
Authors: Hilary C Martin; Grace E Kim; Alistair T Pagnamenta; Yoshiko Murakami; Gemma L Carvill; Esther Meyer; Richard R Copley; Andrew Rimmer; Giulia Barcia; Matthew R Fleming; Jack Kronengold; Maile R Brown; Karl A Hudspith; John Broxholme; Alexander Kanapin; Jean-Baptiste Cazier; Taroh Kinoshita; Rima Nabbout; David Bentley; Gil McVean; Sinéad Heavin; Zenobia Zaiwalla; Tony McShane; Heather C Mefford; Deborah Shears; Helen Stewart; Manju A Kurian; Ingrid E Scheffer; Edward Blair; Peter Donnelly; Leonard K Kaczmarek; Jenny C Taylor Journal: Hum Mol Genet Date: 2014-01-25 Impact factor: 6.150
Authors: Miriam H Meisler; Guy Helman; Michael F Hammer; Brandy E Fureman; William D Gaillard; Alan L Goldin; Shinichi Hirose; Atsushi Ishii; Barbara L Kroner; Christoph Lossin; Heather C Mefford; Jack M Parent; Manoj Patel; John Schreiber; Randall Stewart; Vicky Whittemore; Karen Wilcox; Jacy L Wagnon; Phillip L Pearl; Adeline Vanderver; Ingrid E Scheffer Journal: Epilepsia Date: 2016-06-08 Impact factor: 5.864
Authors: Congyi Lu; Xi Shi; Andrew Allen; David Baez-Nieto; Alexandria Nikish; Neville E Sanjana; Jen Q Pan Journal: FASEB J Date: 2019-01-30 Impact factor: 5.191
Authors: Géza Berecki; Katherine B Howell; Yadeesha H Deerasooriya; Maria Roberta Cilio; Megan K Oliva; David Kaplan; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou Journal: Proc Natl Acad Sci U S A Date: 2018-05-29 Impact factor: 11.205
Authors: Mark A Corbett; Susannah T Bellows; Melody Li; Renée Carroll; Silvana Micallef; Gemma L Carvill; Candace T Myers; Katherine B Howell; Snezana Maljevic; Holger Lerche; Elena V Gazina; Heather C Mefford; Melanie Bahlo; Samuel F Berkovic; Steven Petrou; Ingrid E Scheffer; Jozef Gecz Journal: Neurology Date: 2016-10-12 Impact factor: 9.910
Authors: Katherine B Howell; Stefanie Eggers; Kim Dalziel; Jessica Riseley; Simone Mandelstam; Candace T Myers; Jacinta M McMahon; Amy Schneider; Gemma L Carvill; Heather C Mefford; Ingrid E Scheffer; A Simon Harvey Journal: Epilepsia Date: 2018-05-11 Impact factor: 5.864